ABS公司推出不透辐射的新型骨骼粘合剂

一种新型不透辐射的骨骼粘合剂叫做Symphony VR，被研制在脊椎椎体填充术或者椎体后凸成形术的时候，用于脊椎骨病理性骨折的固定。这种骨骼粘合剂已经获得了美国食品药品管理局的许可。

令人疼痛难忍的脊椎压缩性骨折可能是由于骨质疏松、良性病变（血管瘤）、转移性癌比如骨髓瘤而导致的后果。与使用其它单体产品相比较，这种粘合剂先与不透辐射物质预先混和，使得脊柱医生操作时间更长，操作过程中产热更少。骨骼空腔充填系统叫做Plexis使用获得的混和与输送工艺，保证了外科医生最大程度地控制手术。Symphony VR是ABS公司的产品。

ABS公司总裁兼首席执行官Pete Carr指出：“FDA的许可允许ABS向市场将Plexis混和与输送系统以及ABS的Symphony VR不透辐射的骨骼粘合剂做为整体推广。在脊椎椎体填充术或者椎体后凸成形术的时候，为脊柱医生提供了脊椎压缩性骨折的固定提供了解决方案。”

Radiopaque Bone Cement for Fracture Fixation
 
A new radiopaque bone cement called Symphony VR has been developed for use in the fixation of pathologic fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. The bone cement has been cleared by the U.S. Food and Drug Administration (FDA).

Painful vertebral compression fractures can result from osteoporosis, benign lesions (hemangioma), and metastatic cancers such as myeloma. The cement comes premixed with a radiopacifier, giving a spine doctor longer working time and a lower exothermic temperature while using less monomer than other products. A bone-void filling system called Plexis utilizes a patented mixing and delivery technology that gives the surgeon maximum control. Symphony VR is the product of Advanced Biomaterial Systems, Inc. (ABS, Chatam, NJ, USA; www.advbiomat.com).

“This FDA clearance now allows ABS to market its Plexis mixing and delivery system together with ABS’s Symphony VR radiopaque bone cement as a complete and controlled solution to spine physicians for stabilizing spinal compression fractures for use in either vertebroplasty or kyphoplasty procedures,” noted Pete Carr, president and CEO of ABS.